Vers-chez-les-Blancs and Schlieren, Switzerland, February 16th, 2023 – Nestlé Health Science and EraCal Therapeutics Ltd today announced that they entered into a research collaboration aiming to identify novel nutraceuticals relevant to control food intake.
The joint program combines Nestle’s unique nutraceutical resources with EraCal’s differentiated drug discovery platform. These synergies aim to provide a new paradigm for first-line nutraceuticals for people suffering from metabolic diseases.
Traditional reductionist research strategies (cell lines, organoids, etc) cannot capture whole-organism, multifactorial dynamics associated with metabolic diseases. EraCal‘s custom-built platform overcomes these challenges by combining state-of-the-art microscopy, with the power of large-scale phenotypic drug discovery. The platform is peer-reviewed (https://www.science.org/doi/10.1126/sciadv.aav1966), demonstrates translational success with diverse pharmaceutical modalities, and therefore holds the promise to unlock new biology. The platform has identified novel mechanisms of action and is therefore a prime choice to discover first-in-class compounds.
“Nestlé Health Science knows how to develop nutraceutical compounds as first-line treatment for people in need, thanks to their distinguished commitment to cutting-edge science and clinical validation thereof,” said Josua Jordi, CEO of EraCal. “We are therefore excited to join forces with the world-leading company in the nutritional space and together drive innovation in the metabolic syndrome arena”.
“Metabolic health is an area that we are extremely interested in, specifically how innovative nutritional solutions can help improve the health of patients and consumers,” said Hans-Juergen Woerle, Chief Scientific and Medical Officer of Nestlé Health Science. “Partnering with EraCal on their unique platform, we aim to identify new solutions for weight management.”
About EraCal Therapeutics Ltd:
EraCal Therapeutics Ltd. is a Swiss biotech startup developing a novel anti-obesity drug candidate, named Era-379. Era-379 is an oral-active appetite suppressor with a novel mode of action and originates from an EraCals’ phenotypic drug discovery technology. EraCal Therapeutics Ltd. was founded in September 2018 as a spin-off of the University of Zurich and Harvard University. For more information, visit www.eracal.ch.
About Nestlé Health Science (NHSc):
Nestlé Health Science, a leader in the science of nutrition, is a globally managed business unit of Nestlé. We are committed to redefining the management of health, offering an extensive portfolio of science-based consumer health, medical nutrition, pharmaceutical therapies, and vitamin and supplement brands. Our extensive research network provides the foundation for products that empower healthier lives through nutrition. Headquartered in Switzerland, we have more than 12,000 employees around the world, with products available in more than 140 countries. www.nestlehealthscience.com